{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:50:28Z","timestamp":1762159828389},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1038\/sj.eye.6700035","type":"journal-article","created":{"date-parts":[[2002,9,23]],"date-time":"2002-09-23T13:23:41Z","timestamp":1032787421000},"page":"39-43","source":"Crossref","is-referenced-by-count":13,"title":["A short term study of the additive effect of timolol and brimonidine on intraocular pressure"],"prefix":"10.1038","volume":"16","author":[{"given":"M K","family":"Arici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Sayici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u0130","family":"Toker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Topalkara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,4,5]]},"reference":[{"key":"BF6700035_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/0014-2999(81)90588-4","volume":"72","author":"D Cambridge","year":"1981","unstructured":"Cambridge D . UK \u2013 14,304, a potent and selective \u03b1-agonist for the characterization of \u03b1-adrenoceptor subtypes. Eur J Pharmacol 1981; 72: 413\u2013415","journal-title":"Eur J Pharmacol"},{"key":"BF6700035_CR2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1001\/archopht.1995.01100120044006","volume":"113","author":"CB Toris","year":"1995","unstructured":"Toris CB, Gleason ML, Camras CB, Yablonski ME . Effects of brimonidine on aqueous humour dynamics in human eye. Arch Ophthalmol 1995; 113: 1154\u20131157","journal-title":"Arch Ophthalmol"},{"key":"BF6700035_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0161-6420(97)30349-2","volume":"104","author":"RJ Derick","year":"1997","unstructured":"Derick RJ, Robin AL, Walters TR et al. Brimonidine tartrate: a one month dose response study. Ophthalmology 1997; 104: 131\u2013136","journal-title":"Ophthalmology"},{"issue":"Suppl 2A","key":"BF6700035_CR4","first-page":"156","volume":"5","author":"R David","year":"1995","unstructured":"David R, Walters TR, Sargent JB et al. The safety and efficacy of brimonidine tartrate 0.08%, 0.2%, 0.35% and 0.5% in normotensive subjects. Eur J Ophthalmol 1995; 5 (Suppl 2A): 156 (Abstract)","journal-title":"Eur J Ophthalmol"},{"issue":"Suppl","key":"BF6700035_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0039-6257(96)82030-3","volume":"41","author":"JB Serle","year":"1996","unstructured":"Serle JB the Brimonidine Study Group III. A comparison of the safety and efficacy of twice-daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol 1996; 41 (Suppl): 39\u201347","journal-title":"Surv Ophthalmol"},{"key":"BF6700035_CR6","first-page":"417","volume":"117","author":"JS Schuman","year":"1997","unstructured":"Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K . A 1-year study of brimonidine twice daly in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997; 117: 417\u2013419","journal-title":"Arch Ophthalmol"},{"key":"BF6700035_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/archopht.1995.01100010079024","volume":"113","author":"JR Nordlund","year":"1995","unstructured":"Nordlund JR, Pasquale LR, Robin AL et al. The cardiovascular, pulmonary and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995; 113: 77\u201383","journal-title":"Arch Ophthalmol"},{"issue":"Suppl 1","key":"BF6700035_CR8","first-page":"27","volume":"41","author":"SS Joel","year":"1996","unstructured":"Joel SS . Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996; 41 (Suppl 1): 27\u201337","journal-title":"Surv Ophthalmol"},{"key":"BF6700035_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0149-2918(00)87981-3","volume":"22","author":"S Melamed","year":"2000","unstructured":"Melamed S, David R . Ongoing clinical assessment of the safety and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther 2000; 22: 103\u2013111","journal-title":"Clin Ther"},{"key":"BF6700035_CR10","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/S0161-6420(98)91048-X","volume":"105","author":"RP LeBlanc","year":"1998","unstructured":"LeBlanc RP . Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998; 105: 1960\u20131967","journal-title":"Ophthalmology"},{"key":"BF6700035_CR11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/0014-4835(78)90083-0","volume":"27","author":"ME Yablonski","year":"1978","unstructured":"Yablonski ME, Zimmerman TJ, Waltman SR, Becker B . A fluorophotometric study of the effect of topical timolol on aqueous humour dynamics. Exp Eye Res 1978; 27: 1135\u20131142","journal-title":"Exp Eye Res"},{"key":"BF6700035_CR12","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1001\/archopht.1978.03910060433007","volume":"96","author":"RL Coakes","year":"1978","unstructured":"Coakes RL, Brubaker RF . The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Opthalmol 1978; 96: 2045\u20132048","journal-title":"Arch Opthalmol"},{"key":"BF6700035_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1600-0420.1999.tb01149.x","volume":"77","author":"M Centofanti","year":"1999","unstructured":"Centofanti M, Manni GL, Gregori D, Parisi V, Cocco F, Bucci MG . Brimonidine 0.2% behaviour on intraocular pressure in timolol-uncontrolled glaucomatous patients. Acta Ophthalmol Scand Suppl 1999; 77: 52","journal-title":"Acta Ophthalmol Scand Suppl"},{"key":"BF6700035_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000027427","volume":"213","author":"N Y\u00fcksel","year":"1999","unstructured":"Y\u00fcksel N, Altinta\u015f O, Karaba\u015f L, Alp B, \u00c7a\u011flar Y . The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma. Ophthaomologica 1999; 213: 228\u2013233","journal-title":"Ophthaomologica"},{"key":"BF6700035_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0002-9394(00)00381-0","volume":"129","author":"CW Stewart","year":"2000","unstructured":"Stewart CW, Sharpe ED, Harbin TS, Pastor SA, Day DG, Holmes KT et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol 2000; 129: 723\u2013727","journal-title":"Am J Ophthalmol"},{"key":"BF6700035_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/jop.2000.16.251","volume":"16","author":"WC Stewart","year":"2000","unstructured":"Stewart WC, Sharpe ED, Day DG, Kolker AE, Konstas AG, Lee WH et al. Comparison of efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2000; 16: 251\u2013259","journal-title":"J Ocul Pharmacol Ther"},{"key":"BF6700035_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0149-2918(00)89008-6","volume":"22","author":"ST Simmons","year":"2000","unstructured":"Simmons ST, Samuelson TW . Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. Clin Therapeut 2000; 22: 388\u2013399","journal-title":"Clin Therapeut"},{"key":"BF6700035_CR18","unstructured":"Hoskins HD Jr, Kass MA . Becker\u2013Shaffer\u2019s Diagnosis and Therapy of the Glaucoma, 6th edn CV Mosby: St Louis 1989 Chs 23, 26"},{"key":"BF6700035_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0161-6420(00)00081-6","volume":"107","author":"JS Schuman","year":"2000","unstructured":"Schuman JS . Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology 2000; 107: 1171\u2013117","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6700035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6700035","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6700035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:09:06Z","timestamp":1684411746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6700035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["BF6700035"],"URL":"https:\/\/doi.org\/10.1038\/sj.eye.6700035","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}